Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15803221 | 0.89 | PDK2 (0.45) | ALDH1A1KMT2ATSHRFKBP1ASMN1; SMN2 | |
| SCHEMBL15083158 | 0.89 | PDK2 (0.45) | ALDH1A1KMT2ATSHRFKBP1ASMN1; SMN2 | |
| SCHEMBL29384614 | 0.88 | ALDH1A1 (0.43) | ALDH1A1KMT2ATSHRL3MBTL1FKBP1A | |
| SCHEMBL16288999 | 0.87 | ALDH1A1 (0.43) | ALDH1A1KMT2AFKBP1ASMN1; SMN2F2 | |
| SCHEMBL31683960 | 0.87 | ALDH1A1 (0.43) | ALDH1A1KMT2AFKBP1ASMN1; SMN2F2 | |
| SCHEMBL15083571 | 0.87 | ALDH1A1 (0.43) | ALDH1A1KMT2AFKBP1ASMN1; SMN2F2 | |
| SCHEMBL16316793 | 0.87 | ALDH1A1 (0.44) | ALDH1A1KMT2ASMN1; SMN2F2 | |
| SCHEMBL15805130 | 0.87 | ALDH1A1 (0.44) | ALDH1A1KMT2ASMN1; SMN2F2 | |
| SCHEMBL16316767 | 0.87 | ALDH1A1 (0.44) | ALDH1A1KMT2ASMN1; SMN2F2 | |
| SCHEMBL119560 | 0.85 | ALDH1A1 (0.58) | ALDH1A1KMT2ASMN1; SMN2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3608317-A1 | COMPOUNDS & METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS & OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE | Yale University (US) | 2020-02-12 | — | — | EP | disclosed |
| US-20070225344-A1 | Sulfonamide derivatives to treat infection with hepatitis C virus | WYETH | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225344-A1 | Sulfonamide derivatives to treat infection with hepatitis C virus | HCCS, HAVCR2, SULT2A1 | ALDH1A1 907/4885KDM4E 3418/4885MEN1 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.